SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) Due to Potential for Cross Contamination with a Non-Antibacterial

[FDA]

SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® (ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a nonantibacterial
ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the BREXAFEMME® tab


Baca selengkapnya di : http://www.fda.gov...